Vaccine

Draganfly Announces Q3 Results and Record Nine Months Ended Sep 30/22 Revenue

Retrieved on: 
Wednesday, November 9, 2022
CSE, GLOBE, Exposition, Vaccine, Income, Commander, LLC, EDGAR, International Association of Chiefs of Police, Technology, XL, IACP, UAV, FSE, Mission statement, EDT, NASDAQ, PDT, Corrections, Thermoregulation, International Association, Software, RGB, Company, Conference, Heart, CEO, Commercial, SEDAR, Insurance, Blood pressure, Video game

Gross margin percentage for Q3 2022 was 33.4% compared to 40.8% in Q3 2021 due to the sales mix of the products sold.

Key Points: 
  • Gross margin percentage for Q3 2022 was 33.4% compared to 40.8% in Q3 2021 due to the sales mix of the products sold.
  • Draganfly delivered next-generation Medical Response Drones to Coldchain Delivery Systems, LLC (Coldchain Delivery Systems) for provision to Revived Soldiers Ukraine (RSU).
  • This shipment of Medical Response Drones comes equipped with custom hardware and software updates developed by the Draganfly team.
  • Draganfly will hold shareholder update and earnings call on November 9, 2022, at 2:30 p.m. PDT / 5:30 p.m. EDT.

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, TGF beta 1, Investigational New Drug, IO, TGF beta 2, Forward-looking statement, IND, Vaccine, Tumor microenvironment, Annual general meeting, Nasdaq, Peptide, EST, Immunotherapy, IDO, Center, ARG1, Society for Immunotherapy of Cancer, Securities Act of 1933, Cancer, Herlev Hospital, PD-L1, Securities Exchange Act of 1934, SITC, Time, Vaccination, Science, Transforming growth factor, beta 3, Cell, Patient, TME, Maritime Transportation Security Act of 2002, Society, Antigen, Communications satellite

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, today announced details of the invited oral presentation and two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.

Key Points: 
  • Information for the invited oral presentation:
    Session: Concurrent Session 119 Vaccines: In Situ Agents and Novel Systemic Approaches
    Presenter: Mads Hald Andersen, Ph.D.
  • We see the potential of these two new candidates to build on the strength of our T-win platform and a path forward for Investigational New Drug filings.
  • These preclinical data support further development of a TGF1 vaccine as a TME targeted approach for the treatment of a wide range of cancers.
  • IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through preclinical development its other pipeline candidates.

IO Biotech Announces Third Quarter Results for 2022

Retrieved on: 
Wednesday, November 9, 2022
MSD, GLOBE, Meeting, IO, Head, Forward-looking statement, Poster, Nivolumab, Melanoma, Annual general meeting, Nasdaq, Immunotherapy, Income, Adjuvant, CR, Merck, IDO, ARG1, Hand, Securities Act of 1933, Large-cell lung carcinoma, MOS, Merck & Co., PD-L1, Safety, PD-1, Resection margin, Securities Exchange Act of 1934, SITC, Company, Neoplasm, Pembrolizumab, Research, Clinical trial, Chemistry, Neck, Drug Quality and Security Act, NEW, Multi, Society, Trial of the century, Pharmaceutical industry, Vaccine, Cryptocurrency, Patient

See the following press release for more information, IO Biotech ApS - IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting .

Key Points: 
  • See the following press release for more information, IO Biotech ApS - IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting .
  • Ms. Sullivan brings 30 years of experience building biotech companies to IO Biotech.
  • See the following press release for more information, IO Biotech ApS - IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors .
  • IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform.

GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 9, 2022
Capsid, Pfizer, IND, Travel, Risk, NIH, Lip, Exercise, Delta, Virus, Company, Public health, Security (finance), Immunization, Patent, Thomas Jefferson University, City, MVA, SPX, Immunotherapy, University of North Carolina at Greensboro, U.S. Securities and Exchange Commission, Cancer, Emory University, Vaccination, Research, Stanford University, Patient, CEO, HIV, COVID-19, Investigational New Drug, Mutation, Nasdaq, Webcast, EST, Tongue, GeoVax, HNSCC, Cell, Biotechnology, FDA, GLOBE, Head, NPJ, Severe acute respiratory syndrome coronavirus 2, Primate, US Foods, Safety, Infection, SUDV, University, MPX, Pharmaceutical industry, Vaccine, Monkeypox, Omicron, Smallpox

ATLANTA, GA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results for the third quarter ended September 30, 2022.

Key Points: 
  • ATLANTA, GA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results for the third quarter ended September 30, 2022.
  • GeoVaxs management will host a live conference call and webcast at 4:30 p.m. EST on Wednesday, November 9, 2022, to provide a general business update and discuss financial results.
  • During the November 9th Corporate Update call, GeoVax will provide a progress report on study expansion developments.
  • Management will host a conference call, scheduled to begin at 4:30 p.m. EST today, November 9, 2022, to review financial results and provide an update on corporate developments.

4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Security (finance), Private Securities Litigation Reform Act, Risk, U.S. Securities and Exchange Commission, Interim, Choroideremia, Nasdaq, Research, Tissue, Cystic fibrosis, Fabry, Ophthalmology, Therapy, US, AMD, Safety, Molecule, AAV, D, Program, Clinical trial, Conference, Patient, Cardiology, COVID-19, Fabry disease, Pharmaceutical industry, Vaccine, Lease

EMERYVILLE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today reported third quarter 2022 financial results.

Key Points: 
  • Revenue: Total revenue for the quarter ended September 30, 2022, was $0.5 million, as compared to $1.4 million for the quarter ended September 30, 2021.
  • Net Loss: Net loss was $25.7 million for the quarter ended September 30, 2022, as compared to $22.2 million for the quarter ended September 30, 2021.
  • 4D Molecular Therapeutics, 4DMT, Therapeutic Vector Evolution, and the 4DMT logo are trademarks of 4DMT.
  • Our results for the quarter ended September 30, 2022, are also not necessarily indicative of our operating results for any future periods.

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Retrieved on: 
Wednesday, November 9, 2022
Acumen, GLOBE, Conference, Pathology, ABOS, NASDAQ, Research, Patient, Therapy, Pharmaceutical industry, Vaccine

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimers disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference onWednesday, November 16, 2022at4:10 p.m.

Key Points: 
  • CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimers disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference onWednesday, November 16, 2022at4:10 p.m.
  • The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 14 days.
  • Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimers disease.
  • Acumens scientific founders pioneered research on AOs, which a growing body of evidence indicates are primary triggers of Alzheimers disease pathology.

LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Immunity, Forward-looking statement, Mutation, Inflammation, Ophthalmology, Cancer, SEC, SHP2, Safety, U.S. Securities and Exchange Commission, Survival, Biotechnology, Patient, NSCLC, EGFR, Pharmaceutical industry, Vaccine

In this two-part, open label, dose escalation and dose expansion Phase 1 study, safety and preliminary anti-tumor activity will be examined.

Key Points: 
  • In this two-part, open label, dose escalation and dose expansion Phase 1 study, safety and preliminary anti-tumor activity will be examined.
  • Part 1 is a dose escalation to establish the recommended Phase 2 dose (RP2D) of BBP-398 and assess the pharmacokinetic profile of BBP-398 in Chinese patients.
  • Part 2 is a dose expansion to examine preliminary antitumor activity in patients with advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC).
  • LianBio plans to develop BBP-398 in combination with various oncology medications in solid tumors, including for the treatment of NSCLC.

AnaptysBio to Participate in Upcoming November Investor Conferences

Retrieved on: 
Wednesday, November 9, 2022
SAN, GLOBE, Nasdaq, Webcast, PT, Neurology, Phase II, Guggenheim, GSK, Conference, Therapy, Inflammation, GPP, Vaccine

ET / 10:00 a.m. PT; members of its senior management team will also be hosting investor meetings at the Jefferies London Healthcare Conference on November 16th, 2022.

Key Points: 
  • ET / 10:00 a.m. PT; members of its senior management team will also be hosting investor meetings at the Jefferies London Healthcare Conference on November 16th, 2022.
  • A live audio webcast of the presentation will be available on the investor section of the AnaptysBio website at https://ir.anaptysbio.com/events .
  • AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics.
  • AnaptysBio is also developing imsidolimab, our anti-IL-36R antibody in Phase 3 for the treatment of generalized pustular psoriasis, or GPP.

DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, PPI, Private Securities Litigation Reform Act, Idiopathic pulmonary fibrosis, Forward-looking statement, IND, Psoriasis, Serum, Food, Nasdaq, Psoriasis Area and Severity Index, Research, Conditional sentence, Keratinocyte, Tissue, National Psoriasis Foundation, Association, Inflammatory bowel disease, COVID-19, Bleeding, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Doctor of Philosophy, PASI, Degenerative disease, Goal, DICE, Safety, Epithelium, Autoimmunity, IL-17, Company, Biomarker, Inflammation, Disease, D, Patient, Immune system, Pain, CEO, Infection, Fibroblast, FDA, Pharmaceutical industry, Vaccine

DC-806 was well tolerated with an excellent safety profile across all dose groups in healthy volunteers and psoriasis patients.

Key Points: 
  • DC-806 was well tolerated with an excellent safety profile across all dose groups in healthy volunteers and psoriasis patients.
  • In addition, in October 2022, DICE announced the successful closing of an upsized public offering, raising gross proceeds of $345.0 million.
  • R&D Expenses: Research and development expenses were $14.7 million for the third quarter of 2022, compared to $11.7 million for the same period in 2021.
  • G&A Expenses: General and administrative expenses were $6.4 million for the third quarter of 2022, compared to $4.4 million for the same period in 2021.

Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Wednesday, November 9, 2022
Adult, Interim, IL15, Risk, Sale, Population, G&A, CRS, Rituximab, Cryopreservation, B-cell lymphoma, Cash, Cell, MDS, Security (finance), Mab, Toxic shock syndrome, Neurotoxicity, SEC, Human, U.S. Securities and Exchange Commission, Cancer, AML, Research, Patient, ADCC, CEO, COVID-19, Private Securities Litigation Reform Act, Engineering, Acute myeloid leukemia, NKG2D, R, Antibody, MRD, Infection, CD19, GLOBE, Intellectual property, Tenant, Investment, Graft-versus-host disease, CAR, Safety, CRISPR, ClinicalTrials.gov, D, NK, Interleukin, Aplastic anemia, SITC, Vaccine, Pharmaceutical industry, Lease

Nkarta plans to present additional clinical data from its ongoing Phase 1 clinical trial of NKX019 by year-end 2022 as part of a company-hosted announcement.

Key Points: 
  • Nkarta plans to present additional clinical data from its ongoing Phase 1 clinical trial of NKX019 by year-end 2022 as part of a company-hosted announcement.
  • Nkarta plans to present additional clinical data from its ongoing Phase 1 clinical trial of NKX101 in the first half of 2023.
  • Nkarta updated this timing from year-end 2022 in order to collect a more robust and interpretable data set from a heavily pre-treated and heterogenous patient population.
  • Net Loss: Net loss was $28.3 million, or $0.58 per basic and diluted share, for the third quarter of 2022.